How to Get Vyleesi (Bremelanotide) in Tennessee

What Vyleesi Is and Why Tennessee Providers Prescribe It

Bremelanotide is a melanocortin-4 receptor agonist that the FDA approved in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women [1]. It is the only on-demand injectable approved for this indication. The drug works by activating central nervous system pathways involved in sexual desire rather than targeting peripheral blood flow [2].

HSDD affects an estimated 6 to 10 percent of premenopausal women in the United States, according to prevalence data published in the Journal of Sexual Medicine [3]. In Tennessee, where approximately 1.4 million women fall within the 18-to-49 premenopausal age range per U.S. Census estimates, the potential patient population is significant. Unlike flibanserin (Addyi), which requires daily oral dosing, bremelanotide is used as needed: a single 1.75 mg subcutaneous injection administered at least 45 minutes before anticipated sexual activity [1].

The RECONNECT phase 3 program (two trials, combined N = 1,247) demonstrated that bremelanotide produced a statistically significant increase in desire and a reduction in distress related to low sexual desire compared to placebo over 24 weeks [4]. Mean change from baseline on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 was −1.7 for bremelanotide versus −1.0 for placebo (P < 0.001) [4].

Tennessee Telehealth Rules for Vyleesi Prescriptions

Tennessee permits telehealth prescribing of bremelanotide. The state updated its telehealth framework under Tennessee Code Annotated § 63-1-155, which allows providers to establish a patient-provider relationship through a real-time audio-video encounter [5]. This means a Tennessee-licensed physician, nurse practitioner, or physician assistant can evaluate, diagnose HSDD, and prescribe Vyleesi without requiring an in-person office visit first.

The Tennessee Board of Medical Examiners requires that telehealth consultations meet the same standard of care as in-person visits [5]. For an HSDD evaluation, this typically includes a sexual health history, menstrual status confirmation, medication reconciliation, and screening for confounding factors such as depression or medication-induced sexual dysfunction. The provider must be licensed in Tennessee or hold a valid multistate compact license recognized by the state.

Several national telehealth platforms now serve Tennessee patients seeking HSDD treatment. HealthRX connects patients with board-certified providers who can evaluate for HSDD and prescribe bremelanotide during a single virtual appointment, with prescriptions sent directly to the patient's preferred pharmacy. Wait times for telehealth appointments are often shorter than those for in-person gynecology or sexual medicine referrals, which can average 4 to 6 weeks in metropolitan Nashville or Memphis.

Who Can Prescribe Vyleesi in Tennessee

Three categories of licensed clinicians in Tennessee can write a bremelanotide prescription. MDs and DOs have unrestricted prescribing authority for FDA-approved medications [6]. Nurse practitioners practicing under collaborative agreements, or those with full practice authority (APRN-FPA) as permitted by Tennessee's 2021 legislative update, may also prescribe [7]. Physician assistants prescribe under their supervising physician's delegation [6].

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction recommends that HSDD diagnosis be made by a clinician experienced in sexual medicine, though this is a recommendation rather than a legal requirement [8]. In practice, OB-GYNs, primary care providers, and sexual medicine specialists across Tennessee all prescribe bremelanotide. No additional DEA registration is needed because bremelanotide is not a controlled substance.

A practical point: Tennessee does not restrict bremelanotide prescribing to any single specialty. Any provider comfortable with the HSDD diagnostic criteria in the DSM-5 and the drug's contraindication profile (uncontrolled hypertension, cardiovascular disease) can prescribe it after a thorough evaluation [1].

Required Labs and Clinical Workup Before Prescribing

Before writing a bremelanotide prescription, Tennessee providers typically order baseline labs to rule out organic causes of low desire and confirm prescribing safety. The FDA label lists uncontrolled hypertension and known cardiovascular disease as contraindications [1].

Standard pre-prescribing workup includes:

• Blood pressure (office or home monitoring). Bremelanotide can transiently raise systolic BP by approximately 6 mmHg and diastolic by 3 mmHg, peaking 2 to 3 hours post-dose [1].
• Thyroid panel (TSH, free T4). Hypothyroidism is a recognized contributor to low sexual desire per the American Thyroid Association [9].
• Complete metabolic panel. Liver and renal function markers help assess overall health status.
• Estradiol and testosterone levels. The Endocrine Society recommends measuring total testosterone and free testosterone in women with suspected HSDD to exclude hormonal deficiency [8].
• PHQ-9 or equivalent depression screen. Major depressive disorder and SSRI/SNRI medications are common causes of diminished desire, and the RECONNECT trials excluded women with untreated depression [4].
• Prolactin (if clinically indicated). Hyperprolactinemia can suppress libido and should be excluded [8].

Most commercial labs operating in Tennessee (LabCorp, Quest Diagnostics, and hospital-affiliated labs in Nashville, Knoxville, Chattanooga, and Memphis) can process these panels within 24 to 48 hours. Telehealth providers often send lab orders to a location near the patient before the follow-up visit to review results.

Insurance Coverage and Prior Authorization in Tennessee

Commercial insurance coverage for Vyleesi varies by plan, and most Tennessee insurers require prior authorization before dispensing. The brand-name autoinjector carries a wholesale acquisition cost of approximately $900 for four single-use doses [10].

TennCare (Tennessee Medicaid) does not cover Vyleesi for HSDD. The TennCare formulary excludes most sexual health medications outside of erectile dysfunction treatments for qualifying male beneficiaries.

BlueCross BlueShield of Tennessee, the state's largest commercial insurer, generally requires prior authorization documentation showing:

1. A confirmed DSM-5 diagnosis of HSDD in a premenopausal woman.
2. Documentation that the condition is not caused by a co-existing medical or psychiatric condition, medication, or relationship factors.
3. Evidence that non-pharmacologic approaches (therapy, psychoeducation) were considered.
4. Absence of contraindications listed on the FDA label [1].

Cigna, UnitedHealthcare, and Aetna plans operating in Tennessee follow similar prior authorization pathways. Average turnaround time for PA decisions is 3 to 5 business days per Tennessee Department of Commerce and Insurance guidelines [11]. If a PA is denied, Tennessee patients have the right to an external review under TCA § 56-7-2301.

Palatin Technologies offers a patient savings card that can reduce out-of-pocket costs to as low as $50 per prescription for commercially insured patients, though this benefit does not apply to government-funded insurance [10].

Pharmacy Access and 503A Compounding in Tennessee

Tennessee patients have two pharmacy pathways for obtaining bremelanotide: brand-name Vyleesi through retail or specialty pharmacies, and compounded bremelanotide through 503A-licensed compounding pharmacies.

Retail and specialty pharmacy. Major chains (CVS, Walgreens, Kroger Pharmacy) across Tennessee can order and dispense the brand-name Vyleesi autoinjector. Specialty pharmacies affiliated with major health systems in Nashville (Vanderbilt, TriStar) and Memphis (Methodist Le Bonheur) also stock or can order the drug. Patients using a specialty pharmacy may receive injection training as part of the dispensing process.

503A compounding. Tennessee's Board of Pharmacy licenses 503A compounding pharmacies under TCA § 63-10-204, which permits pharmacist-prepared patient-specific prescriptions [12]. A Tennessee-licensed 503A pharmacy can compound bremelanotide acetate for subcutaneous injection when a valid prescription is presented. Compounded formulations may offer cost savings compared to the brand autoinjector, particularly for patients paying out of pocket or those whose insurance denies coverage.

The FDA requires that 503A compounding pharmacies prepare medications pursuant to individual prescriptions and comply with USP <797> sterile compounding standards [13]. Tennessee 503A pharmacies must also register with the state and maintain compliance with Tennessee Board of Pharmacy regulations. Patients should confirm that any compounding pharmacy they use holds a current Tennessee state license and follows USP <797> guidelines for sterile preparations.

Shipping is permitted within Tennessee for 503A pharmacies holding the appropriate state license, so patients in rural areas without nearby compounding facilities can receive bremelanotide by mail [12].

How Long It Takes to Receive Vyleesi in Tennessee

Timeline from initial consultation to first dose depends on the prescribing pathway and insurance status.

Telehealth pathway (fastest). A patient can complete a telehealth HSDD evaluation within 1 to 3 days of requesting an appointment. If labs are already available or ordered through a rapid-turnaround lab, the provider can prescribe at the follow-up review. Brand Vyleesi is typically available at a Tennessee retail pharmacy within 1 to 2 business days of prescription submission. Total time: 5 to 10 days.

In-person pathway. Scheduling an initial appointment with a gynecologist or sexual medicine specialist in Tennessee may take 2 to 6 weeks, depending on location and provider availability. After evaluation and labs, a follow-up visit adds another 1 to 2 weeks. Total time: 3 to 8 weeks.

With prior authorization. Add 3 to 5 business days for commercial PA processing. If denied and appealed, Tennessee law requires a decision within 20 business days for standard appeals [11].

Compounded bremelanotide. 503A pharmacies in Tennessee typically require 3 to 7 business days for preparation and shipping of a compounded subcutaneous injection.

Safety Profile and Monitoring After Starting Bremelanotide

The RECONNECT trials documented nausea as the most common adverse event, occurring in 40.0% of bremelanotide-treated patients versus 1.3% on placebo [4]. Nausea was dose-limiting in 8% of participants. Flushing occurred in 20.3%, injection site reactions in 12.6%, and headache in 11.3% [4]. These side effects were generally mild to moderate and decreased with repeated dosing.

The FDA label carries specific warnings relevant to Tennessee prescribers [1]:

• Blood pressure elevation. Bremelanotide is contraindicated in patients with uncontrolled hypertension or known cardiovascular disease. Transient blood pressure increases (mean +6/+3 mmHg) resolve within 12 hours [1].
• Focal hyperpigmentation. The melanocortin receptor mechanism can cause darkening of gums, face, and breasts. In RECONNECT, 1% of patients developed hyperpigmentation that did not fully resolve after discontinuation [4].
• Dosing limits. No more than one dose in 24 hours and no more than 8 doses per month [1].
• Naltrexone interaction. Bremelanotide may reduce the efficacy of oral naltrexone. Patients on naltrexone for alcohol use disorder or opioid dependence should not use bremelanotide [1].

Tennessee providers should schedule a follow-up visit or telehealth check-in 4 to 6 weeks after the first dose to assess efficacy, tolerability, and blood pressure response per the manufacturer's recommendation and ISSWSH guidance on HSDD pharmacotherapy follow-up [14].

Transferring an Existing Vyleesi Prescription to Tennessee

Patients relocating to Tennessee from another state can transfer an active Vyleesi prescription. Tennessee Board of Pharmacy rules allow inbound prescription transfers from any U.S. state [12]. The receiving Tennessee pharmacy contacts the originating pharmacy to verify and transfer the prescription record.

For compounded bremelanotide, a new prescription from a Tennessee-licensed provider is required because 503A preparations are patient-specific and pharmacy-specific under federal law [13]. A telehealth consultation can expedite this process, often completing the new prescription within a single virtual visit if the patient provides prior medical records and lab results.

Patients transferring from states with different telehealth regulations should note that Tennessee's telehealth framework is relatively permissive. The state does not require a prior in-person visit before establishing a telehealth relationship for non-controlled substances like bremelanotide [5].

HSDD Diagnostic Criteria Providers Use in Tennessee

Tennessee clinicians diagnose HSDD using DSM-5 criteria for Female Sexual Interest/Arousal Disorder (FSIAD), which consolidated the previous DSM-IV categories of HSDD and female sexual arousal disorder [15]. The diagnosis requires:

1. Absent or significantly reduced sexual interest/desire persisting for at least 6 months.
2. Clinically significant distress related to the reduced desire.
3. The dysfunction is not better explained by a nonsexual mental disorder, relationship distress, substance use, or another medical condition.

The International Society for the Study of Women's Sexual Health (ISSWSH) published a process-of-care algorithm for HSDD that many Tennessee providers follow [14]. This algorithm recommends biopsychosocial assessment, addresses modifiable contributing factors first, and positions FDA-approved pharmacotherapy (bremelanotide or flibanserin) as appropriate when non-pharmacologic interventions are insufficient.

Validated screening tools include the Decreased Sexual Desire Screener (DSDS), which takes under 5 minutes to administer and has a sensitivity of 83.6% for HSDD [16]. Several Tennessee telehealth platforms incorporate the DSDS or equivalent screening into their intake questionnaires to simplify evaluation.